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sensitivity (0.94), speciﬁcity (0.96), PPV (0.978) and Youden’s index
(0.9). The surface protein expression of KIR3DL1, measured by ﬂow
cytometry (DX9) correlated well with the relative expression by Q-
PCR (r  .418; P  .027). We then applied the Q-PCR assay to 3
discrete subpopulations of blood NK cells sorted using a cocktail of 3
antibodies (GL183, EB6 and DX9) that recognize 6 KIR genes
(CD56bright, CD56dimKIRAb, and CD56dimKIRAb-). Com-
pared to the combined CD56dimcell populations, CD56brightNK
cells (thought to be developmentally immature) had lower levels of
gene expression for all KIR except 2DL4. Interestingly, the
CD56dimKIRAb cells expressed higher amounts of the 7 KIR
genes not included in the sorting cocktail than did the
CD56dimKIR cells (median ratio of 5.05; P  .0001). The
CD56dimKIRAb cells had low gene expression for all KIR.
KIR2DL4, which is regulated differently than the other KIR, was the
most highly expressed gene in the CD56dimKIRAbcells. Addition-
ally, CD56dimKIRAb cells express a compensatory rise in NKG2A
(which precedes KIR expression duringNK development) when com-
pared to a CD56dimKIRAb population using ﬂow cytometry
(75.3 12.5% vs 32.0 6.6%; P .038). This demonstrates that the
mature, circulating population of CD56dim NK cells is comprised of
KIR-expressing and KIR-negative populations. Together, these re-
sults suggest that KIR expression may be a marker of maturation with
KIR acquisition under a common locus control mechanism. It also
identiﬁes a large population of mature NK cells lacking inhibitory
KIR that have the potential to become alloreactive if other inhibitory
interactions can be evaded.
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THE CLINICAL USE OF DONOR-DERIVED VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES REACTIVE AGAINST CYTOMEGALOVIRUS (CMV), ADE-
NOVIRUS, AND EPSTEIN BARR VIRUS (EBV)
Bollard, C.M.1, Myers, G.D.1, Leen, A.1, Huls, H.1, Buza, E.1,
Chang, J.3, Leung, K.1, Carrum, G.1, Krance, R.A.1, Molldrem, J.2,
Brenner, M.K.1, Rooney, C.M.1, Heslop, H.E.1 1. Center for Cell and
Gene Therapy, Baylor College of Medicine, Houston, TX; 2. M. D.
Anderson Cancer Center, Houston, TX; 3. Department of Pathology,
The Methodist Hospital, Houston, TX.
CMV, Adenovirus (Ad), and EBV are major viral pathogens post
allogeneic SCT. Adoptive immunotherapy with donor-derived Cy-
totoxic T Lymphocytes (CTL) can prevent the clinical manifesta-
tions of EBV and CMV. We have extended these studies by
generating CTL from donor PBMC that can restore cellular im-
munity to CMV, EBV, and Ad simultaneously. Our protocol uti-
lizes stimulation with mononuclear cells transduced with a recom-
binant Ad type 5 vector pseudotyped with a type 35 ﬁber carrying
a transgene for the CMV antigen pp65, followed by 2 stimulations
with EBV-lymphoblastoid cell lines transduced with the same
vector. After 3 stimulations, 10 CTL cultures contained a mean of
83% (range 8.4–98.99%) CD8ve and a mean of 19.6% (range
2.2–91.6%) CD4ve cells. In Cr release /or IFNELISPOT
assays, all CTL lines showed speciﬁc activity against CMV and
EBV targets; 9/10 lines also showed speciﬁcity against Ad targets.
Further, using MHC-peptide multimers we have demonstrated the
simultaneous presence of CD8ve cells recognizing peptide
epitopes from CMV pp65 (range 2.32–21%) and Ad hexon (1.07–
8.08%) in the CTL cultures. We have treated 6 patients in this
phase I CMV prophylaxis study, 3 on DL1(1  107/m2) and 3 on
DL2(5 107/m2). Patients received one infusion of virus-speciﬁc
CTL from 54–120 days post SCT. We observed up to a 28-fold
increase in CMV pentamer ve CD8 T cells post CTL. At last
follow-up (12–40 wks post CTL infusion) all patients are CMV
and EBV neg. Two patients were transiently ve for CMV by
PCR 4–9 weeks post CTL but both were neg 7 days later without
anti-viral therapy, with a corresponding rise in CMV-speciﬁc CTL
detected in the peripheral blood. Two patients were culture ve
for Ad in stool/ blood pre-CTL therapy. One of these patients
was infected with Ad species from subgroups A, C, and D and the
other with group C alone. In both patients, we observed a 2-log
reduction of adenoviral load within 2–3 weeks post CTL infusion
at which time their symptoms (fever, loose stools) resolved. In
summary, we can efﬁciently generate multi-virus speciﬁc CTL.
Infusion of these cells included virus-speciﬁc CD8ve T cells in
the peripheral blood post CTL infusion. Further, reduction in Ad
load in stool/blood suggests efﬁcacy of Ad-speciﬁc CTL in vivo.
However, expansion of virus-speciﬁc CTL in vivo may require
presence of antigen. We will complete this prophylaxis study and
then proceed to using virus-speciﬁc CTL for the treatment of
CMV and Ad disease post SCT.
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ENHANCED IMMUNE RECONSTITUTION AND FUNCTION BY
CD4CD25 REGULATORY T CELLS FOLLOWING ALLOGENEIC HEMA-
TOPOIETIC CELL TRANSPLANTATION
Nguyen, V.H.1, Shashidar, S.1, Chang, D.S.1, Zeiser, R.1,
Brown, J.M.Y.1, Negrin, R.S.1 Stanford University School of Medicine,
Stanford, CA.
Regulatory T cells (Treg) reduce the incidence and severity of
acute graft-versus-host disease (GvHD) in murine models of ma-
jor-MHC mismatched hematopoietic cell transplantation (HCT).
It is unclear whether the effect of Treg on effector T cells is a
selective or nonselective process or if Treg regulate the process of
intrathymic and peripheral T cell maturation and selection follow-
ing HCT. The current study assessed the impact of Treg on the
quantitative and functional lymphoid reconstitution after HCT.
Treg from FVB/N (H2q) mice were co-transplanted into lethally
irradiated Balb/c (H2d) host along with FVB/N T cell depleted
bone marrow cells and CD4/CD8 cells, the latter to induce
GvHD. At days 14 and 40 post-transplantation, total lymphoid
reconstitution was delayed in the GvHD group and enhanced in
recipients transplanted with Treg (P  .0005 on day 14, P  .0001
on day 40). T cell reconstitution, particularly CD4 cells, was
enhanced in the Treg group at both time points and reached
statistical signiﬁcance on day 40 (P  .003). The number of donor
natural killer cells was particularly increased on day 14 in the Treg
recipients (P  .0003). B-cell reconstitution was enhanced at day
40 in recipient animals that received Treg (P  .006). T cell
repertoire assessed by V-beta TCR screening with FACS analysis
showed a polyclonal distribution. To determine if the improved
and diverse lymphoid reconstitution is associated with increased
immune function, mice were challenged with murine CMV intra-
peritoneally at day 14. Two weeks after infection, 66% of animals
that received Treg in addition to Tcon, and 11% of animals that
received Tcon alone were alive (P  .05). Uninfected mice in the
respective groups served as controls to separate the effect of CMV
infection and GvHD on survival. Compared to infected animals,
no deaths were observed in the respective uninfected groups at this
time point (Tcon alone, P  .0004; Treg  Tcon, P  .21). In
both infected and control uninfected animals, Treg treated animals
had no evidence of signiﬁcant clinical GvHD compared to animals
that received Tcon alone. Decreased viral load and increased
CMV-speciﬁc T cell response in the Treg group conﬁrmed sur-
vival outcomes (P  .05). These ﬁndings indicate that Treg en-
hance both the quantitative and functional recovery of the lym-
phoid cell populations while providing protection against GvHD.
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ACCELERATED IMMUNE RECOVERY FOLLOWING LLME TREATED DO-
NOR LYMPHOCYTE INFUSION
Filicko, J.1, Grosso, D.1, Flomenberg, P.R.1, Brunner, J.1, Dessain, S.1,
Drobyski, W.2, Ferber, A.1, Friedman, T.3, Kahkniashvili, I.1,
Keever-Taylor, C.2, Mookerjee, B.1, Wagner, J.L.1, Korngold, R.3,
Flomenberg, N.1 1. Thomas Jefferson University, Philadelphia, PA; 2.
Medical College of Wisconsin, Milwaukee, WI; 3. Hackensack University
Cancer Center, Hackensack, NJ.
Delayed immune reconstitution is a major cause of morbidity and
mortality after T cell depleted allogeneic progenitor cell transplant
(PCT). To accelerate immune reconstitution without GVHD, we
have administered escalating doses of L-leucyl-L-leucine methyl
ester (LLME) treated lymphocytes (DLI) to 18 patients post
CD34 cell-enriched PCT in an ongoing phase I trial. LLME’s
cellular toxicity occurs after polymerization by dipeptidyl pepti-
dase, leading to selective depletion of cells with cytotoxic effector
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granules containing perforin. Products treated with LLME dem-
onstrated a median depletion of 94.9% CD56 cells, 75.8 %
CD8 cells, but only 37.2% CD4 cells. Patients initially re-
ceived 10e4 (haploidentical (HAPLO)), 10e5 (HLA identical un-
related (URD)), or 10e6 (HLA identical sibling (SIB)) CD3
cells/kg in cohorts of 3, and were eligible for additional infusions at
a one log higher dose after 28 days if there was no evidence of
GVHD or the CD4 count was less than the target of 100 cells/ml.
The initial dose was escalated by one log in subsequent cohorts if
no complications were observed in the previous cohort. Nine
patients received grafts from SIBs (4 at 10e6, 5 at 10e7), six from
URDs (3 at10e5, 3 at 10e6), and three from HAPLOs (3 at 10e4).
All patients had pre-DLI CD4 counts of 5.0 cells/ml, and re-
ceived 1 to 3 infusions post PCT. Since ATG was used during
PCT cytoablation, the ﬁrst DLI infusions were administered after
ATG levels were2 mcg/ml. After DLI #1, 6/8 evaluable matched
SIB recipients and 2/6 evaluable URD recipients demonstrated
early recovery of donor derived CD4 cells prior to day 35 s/p
DLI, with a median CD4 count of 139 cells/ul (range 57–471).
Ten of these achieved a CD4 count above 100 after 1–3 total
infusions. In contrast, none of the haploidentical recipients (receiv-
ing the smallest doses) had an increase in CD4 counts. Five
patients developed GVHD (Grade I–II (n 4), Grade III (n  1
following 410e7 LLME DLI). In recovering patients, spectra-
type analysis of CD4 cells comparing DLI before LLME treat-
ment with lymphocytes recovered from the patients post DLI
demonstrated that 94% of the resolvable Vb families were equally
complex. Perforin positive cells, as well as adenovirus (n 2), EBV
(n  1) and CMV (n  2) speciﬁc lymphocytes, also recovered
post-PCT in these patients. These preliminary results suggest that
LLME treated DLI can accelerate CD4 reconstitution without
causing severe GVHD.
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REGULATORY T CELL (Treg) RECONSTITUTION FOLLOWING T CELL
DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION—KINETICS
OF RECOVERY AND RELATIONSHIP WITH GVHD
Rezvani1, K., Mielke1, S., Ahmadzadeh1, M., Savani1, B., Kilical1, Y.,
Hensel1, N., Kurlande1, R., Barrett1, A.J. National Institutes of Health,
Bethesda, MD.
Regulatory T cells (Treg) that speciﬁcally express the Foxp3
transcriptional repressor are instrumental in the maintenance of
tolerance. They may suppress GVHD and regulate lymphocyte
recovery after SCT. Animal transplantation models show that
Tregs suppress GVHD. However, current data in humans on the
impact of Tregs on GVHD following SCT is conﬂicting, possibly
due to differences in surface phenotyping techniques used to char-
acterize these cells. To characterize Treg recovery and the rela-
tionship with acute GVHD we studied CD4 CD25 Foxp3 T
cells reconstitution in the ﬁrst 120 days following a T-depleted
allogeneic SCT in 17 patients with leukemia. We used surface
phenotyping for CD4 and CD25, intracellular staining for Foxp3
protein, Foxp3 gene expression and functional assays to deﬁne
Treg cells. We found a strong correlation between Foxp3 gene
expression and Foxp3 CD4 T cell number by intracellular
staining. There was a direct correlation between Foxp3 gene ex-
pression and CD4 CD25 T cell numbers in healthy donors.
Interestingly, this strict correlation was lost in patients with leu-
kemia post-SCT due to a disparity between CD4 CD25 and
CD4 Foxp3 T cell numbers in some patients, most likely
related to expansion of the CD4 CD25 Foxp3 effector T cell
population. Although, the proportion of CD4 T cells that are
CD25 reached normal as early as 30 days post-SCT (median 5.0,
range 2.0–8.9), absolute circulating Treg numbers were low in the
ﬁrst 30–45 days post-SCT reaching near-normal levels by day 120,
indicating that Tregs generally recover at a similar rate to CD4
CD25 T cells. However higher day 30 Foxp3 gene expression
inversely correlated with the development of grade II–IV acute
GVHD (P  .02) suggesting that suppressor activity rather than
Treg numbers may be more relevant to GVHD suppression. Chi-
merism analysis was performed on sorted CD4 CD25 and
CD4 CD25 T cell fractions from leukapheresis samples col-
lected 120 days post transplant on 7 patients. In most patients, the
expanded Treg population was enriched in cells of donor origin.
Our results suggest that early Treg reconstitution may affect the
development of GVHD. These results suggest that Treg function
(as measured by Foxp3 gene expression) is important in controlling
alloreactions post-transplant. Our data support the use of ex vivo
expanded activated Tregs given in the ﬁrst 30 days post SCT to
prevent acute GVHD.
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GANCICLOVIR SUPPRESSES HUMAN T LYMPHOCYTE PROLIFERATION
IN VITRO
Battiwalla, M.1, Wu, Y.1, Radovic, M.3, Nakamura, R.2,
Bajwa, R.P.S.1, Elefante, A.1, Segal, B.1, Almyroudis, N.1,
McCarthy, P.L.1 1. Roswell Park Cancer Institute, Buffalo, NY; 2. City
of Hope, Duarte, CA; 3. State University of New York, Buffalo, NY.
Clinically signiﬁcant cytomegalovirus (CMV) infection in allo-
geneic blood or marrow transplant recipients has dramatically
declined in recent years by prophylactic or preemptive therapy
with ganciclovir (GCV). However, patients at risk for CMV reac-
tivation (seropositive donor and/or recipient) consistently have
worse outcomes than patients who are not at risk for CMV reac-
tivation. We have previously shown that even in the absence of
overt CMV disease, persisting post-transplant antigenemia pre-
dicts for increased late relapse and treatment failure (Nakamura et
al BBMT 2004). In other words, frequent CMV reactivation serves
as a surrogate for impaired post-transplant immune reconstitution.
To explain the observed association between CMV reactivation
and relapse, we also raised the possibility that several weeks of
GCV therapy could exert a deleterious effect on a fragile immune
system. We present in vitro data that GCV inhibits normal human
T-lymphocytes and identify the mechanism of immunosuppres-
sion. Human PBMCs were extracted from normal volunteers and
subjected to mitogenic (PHA) or antigen-speciﬁc (CMV-antigen)
stimulation in the absence or presence of varying concentrations of
GCV. Thereapeutic concentrations of GCV greatly reduced both
PHA-induced as well as antigen-speciﬁc T cell proliferation in
vitro compared to foscarnet. The uptake of 3[H]-thymidine by
PBMCs after 5 days incubation in RPMI-10% AB serum was
reduced by 35% at peak therapeutic concentrations (10 mcg/ml) of
GCV as opposed to 73% by Tacrolimus (10ng/ml). GCV did not
induce apoptosis of the Raji (B cell, Burkitt’s leukemia) cell line nor
did it induce apoptosis of normal peripheral blood lymphocytes in
the presence or absence of stimulation. Flow cytometry-based
BrdU incorporation assays show that GCV exerts a time-depen-
dent impairment of DNA synthesis in lymphocytes. Collectively,
these results show that GCV is a potent suppressor of T-lympho-
cyte proliferation in vitro at therapeutic concentrations and the
likely mechanism of action is inhibition of DNA synthesis. GCV
therapy in BMT patients probably increases the level and/or du-
ration of overall T cell immunosuppression and may account for
the differences in clinical outcome.
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INSULIN-LIKE GROWTH FACTOR I IS A POSITIVE REGULATOR OF
THYMIC FUNCTION
Chu, Y.-W.1, Schmitz, S.1, Choudhury, B.1, Gress, R.1 Experimental
Transplantation and Immunology Branch, National Cancer Institute,
Bethesda, MD.
Neuroendocrine growth factors have been implicated to play a
role in regulating thymic function and serve as potential agents to
accelerate thymic T cell production following hematopoietic stem
cell transplantation (HSCT). We present evidence supporting in-
sulin-like growth factor I (IGF-1) as a thymic regulator. Contin-
uous 2-week infusions of IGF-1 (100 ug/day) into young adult
mice resulted in signiﬁcant increases in muliple thymocyte sub-
populations, including early CD4-CD8- subpopulations and ear-
liest thymocyte precursors (ETP). BrdU incorporation with con-
tinuous oral administration was also increased in these populations,
suggesting a stimulatory effect of IGF-1 on thymocyte prolifera-
tion and developmental kinetics. Expansion of peripheral naive T
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